Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized intra-patient dose-finding study of I-020502 in autologous meshed skin grafting
2008-005115-17Phase 2Active
- Sponsor
- Kuros Biosciences
- Start
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of KUR-212 in burn injury and thermal injury, sponsored by Kuros Biosciences. Primary endpoint: Incidence of full wound closure at each test site on Day 12. Started Jun 2009; status: active.
02
Drugs
KUR-212
03
Conditions
burn injurythermal injury
Beyond the preview
Go deeper on 2008-005115-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005115-17.